Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1632477 | 0.97 | L3MBTL1 (0.45) | L3MBTL1ATMPOLBMEN1KMT2A | |
| SCHEMBL22003894 | 0.84 | — | — | |
| SCHEMBL2261416 | 0.84 | POLB (0.42) | L3MBTL1ATMPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL18825205 | 0.77 | LMNA (0.43) | ATMMEN1KMT2AHTTNPSR1 | |
| SCHEMBL48487 | 0.77 | POLB (0.45) | L3MBTL1ATMPOLBMEN1KMT2A | |
| SCHEMBL19147806 | 0.77 | L3MBTL1 (0.38) | L3MBTL1ATMPOLBMEN1KMT2A | |
| SCHEMBL490219 | 0.77 | CA1 (0.52) | L3MBTL1ATMPOLBMEN1KMT2A | |
| SCHEMBL2778744 | 0.74 | POLB (0.43) | L3MBTL1ATMPOLBMEN1KMT2A | |
| SCHEMBL9663002 | 0.74 | POLB (0.43) | L3MBTL1ATMPOLBMEN1KMT2A | |
| SCHEMBL799178 | 0.74 | L3MBTL1 (0.50) | L3MBTL1ATMPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746966-A1 | 4-AMINO-2,6-BIS(PHENYLMETHYLENE)CYCLOHEXANONES AND THEIR USE | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) | 2026-05-27 | — | — | EP | disclosed |
| US-20250275959-A1 | COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250188078-A1 | SMALL MOLECULE INHIBITORS OF THE CRL4 UBIQUITIN LIGASE | CORNELL UNIVERSITY (US) | 2025-06-12 | — | — | US | disclosed |
| EP-3917907-B1 | MODULATORS OF POTASSIUM ION CHANNELS AND USES THEREOF | UNIV DEGLI STUDI DI SALERNO (IT) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025021236-A1 | 4-AMINO-2,6-BIS(PHENYLMETHYLENE)CYCLOHEXANONES AND THEIR USE | Ustav Organicke Chemie A Biochemie AV CR v.v.i. (CZ) | 2025-01-30 | — | — | WO | disclosed |
| EP-4490160-A2 | SMALL MOLECULE INHIBITORS OF THE CRL4 UBIQUITIN LIGASE | Cornell University (US) | 2025-01-15 | — | — | EP | disclosed |
| CN-118496238-A | Macrocyclic compound, preparation method and application thereof, and pharmaceutical composition | 南京得恒医药科技有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-117858879-A | CDK2/4/6 inhibitor and preparation method and application thereof | 南京再明医药有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117430599-A | Cyclin dependent kinase inhibitors | 南京再明医药有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-11858922-B2 | Sulfonylureas and related compounds and use of same | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-01-02 | — | — | US | disclosed |
| EP-0526004-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1993-02-03 | — | — | EP | disclosed |
| US-5164388-A | Hypotensive agents, treatment of congestive heart failure | ABBOTT LABORATORIES (US) | 1992-11-17 | — | — | US | disclosed |
| WO-1992013545-A1 | ENDOTHELIN CONVERTING ENZYME INHIBITORS | ABBOTT LABORATORIES (US) | 1992-08-20 | — | — | WO | disclosed |
| EP-0439556-A4 | HETEROCYCLIC PEPTIDE RENIN INHIBITORS | — | 1991-10-30 | — | — | EP | disclosed |
| EP-0439556-A1 | HETEROCYCLIC PEPTIDE RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1991-08-07 | — | — | EP | disclosed |
| WO-1990004917-A1 | HETEROCYCLIC PEPTIDE RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1990-05-17 | — | — | WO | disclosed |
| EP-0365992-A1 | Heterocyclic peptide renin inhibitors | ABBOTT LABORATORIES (US) | 1990-05-02 | — | — | EP | disclosed |
| EP-0119050-B1 | DIHYDROPYRIDINE ANTI-ISCHAEMIC AND ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1989-03-22 | — | — | EP | disclosed |
| US-4590195-A | ANTIISCHEMIC AGENTS | PFIZER INC. (US) | 1986-05-20 | — | — | US | disclosed |
| EP-0119050-A2 | Dihydropyridine anti-ischaemic and antihypertensive agents | Pfizer Limited (GB) | 1984-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858922-B2 | Sulfonylureas and related compounds and use of same | NLRP3, NOD1, PYCARD | L3MBTL1 2792/4885ATM 2517/4885POLB 4795/4885 |
| US-20250188078-A1 | SMALL MOLECULE INHIBITORS OF THE CRL4 UBIQUITIN LIGASE | DDB1, CUL4A, CUL4B | L3MBTL1 856/4885ATM 1290/4885POLB 96/4885 |
| US-20250275959-A1 | COMPOUNDS AND METHODS OF THEIR USE | ACSL5, ACSL3, ACSL6 | L3MBTL1 4747/4885ATM 2185/4885POLB 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.